Protalex Announces Preliminary Results in Phase I Clinical Trial

Protalex Announces Preliminary Results in Phase I Clinical Trial: "NEW HOPE, Pa.--(BUSINESS WIRE)--Protalex, Inc. (OTC BB: PRTX) announces that dosing has now completed for its expanded single-dose Phase I clinical trial of its lead compound, PRTX-100. This study was performed in healthy volunteers, and was designed primarily to increase the safety database for doses of 0.3 and 0.45 �g/kg of intravenously administered drug. Other objectives for this study were to better characterize the terminal clearance at higher doses, to evaluate a dose 50% higher than that dosed in the initial Phase I study, to evaluate several additional safety biomarkers, including platelet function, and to evaluate changes in monocyte and lymphocyte gene expression following PRTX-100 treatment."